{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:31:20Z","timestamp":1787045480380,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.adro.2026.102096","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:46:15Z","timestamp":1780641975000},"page":"102096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physician- and Patient-Reported Outcomes Following Contemporary Image Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results From the Prospective PRO-Cube Study"],"prefix":"10.1016","volume":"11","author":[{"given":"Sham","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0491-7935","authenticated-orcid":false,"given":"Srinivas","family":"Chilukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan","family":"Arjunan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilasha","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalakshmi","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith K.","family":"Mullapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivathsan","family":"Ramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimhan","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Jawahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaykanth","family":"Amalachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayananda Shamurailatpam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.102096_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2026.102096_bib0002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy","volume":"53","author":"Paganetti","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0003","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1053\/clon.2002.0174","article-title":"The relative costs of proton and X-ray radiation therapy","volume":"15","author":"Goitein","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2026.102096_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/cco.2016.06.03","article-title":"Cost-comparativeness of proton versus photon therapy","volume":"5","author":"Verma","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/pro6.1149","article-title":"A review of proton therapy \u2013 Current status and future directions","volume":"6","author":"Mohan","year":"2022","journal-title":"Precis Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0006","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0007","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2024.09.043","article-title":"Setting the stage: Feasibility and baseline characteristics in the PARTIQoL trial comparing proton therapy versus intensity modulated radiation therapy for localized prostate cancer","volume":"121","author":"Wisdom","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14338\/IJPT-21-00042.1","article-title":"Comparison of estimated late toxicities between IMPT and IMRT based on multivariable NTCP models for high-risk prostate cancers treated with pelvic nodal radiation","volume":"9","author":"Chilukuri","year":"2022","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.adro.2026.102096_bib0009","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ijrobp.2007.07.2335","article-title":"Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer","volume":"70","author":"Vargas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ijrobp.2009.01.044","article-title":"Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer","volume":"75","author":"Chera","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0011","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0012","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2016.02.038","article-title":"Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer","volume":"95","author":"Bryant","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0013","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COC.0000000000000285","article-title":"Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities","volume":"41","author":"Zaorsky","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate-only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0016","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2026.102096_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.adro.2019.01.005","article-title":"Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer","volume":"4","author":"Schad","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0018","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1088\/0031-9155\/53\/17\/023","article-title":"Clinical implementation of full Monte Carlo dose calculation in proton beam therapy","volume":"53","author":"Paganetti","year":"2008","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.adro.2026.102096_bib0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1118\/1.3021139","article-title":"Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning","volume":"36","author":"Unkelbach","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0020","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1118\/1.3556559","article-title":"Minimax optimization for handling range and setup uncertainties in proton therapy","volume":"38","author":"Fredriksson","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.adro.2026.102096_bib0022","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2026.102096_bib0023","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2026.102096_bib0024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0025","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.adro.2026.102096_bib0026","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0027","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0028","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0029","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0031","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2026.102096_bib0032","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.adro.2026.102096_bib0034","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ijrobp.2025.06.1103","article-title":"Quality of Life Results from NRG-GU005: A phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer","volume":"123","author":"Yu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/0284186X.2021.2016948","article-title":"Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer","volume":"61","author":"Henderson","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00031.1","article-title":"Consensus statement on proton therapy for prostate cancer","volume":"8","author":"Bryant","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.adro.2026.102096_bib0037","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","article-title":"Stereotactic body proton therapy versus conventionally fractionated proton therapy for early prostate cancer: A randomized, controlled, phase 3 trial","volume":"120","author":"Toesca","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.adro.2026.102096_bib56","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/0284186X.2017.1388539","article-title":"Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial","volume":"57","author":"Chuong","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0038","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2004.09.042","article-title":"The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: A comparative study","volume":"61","author":"van Lin","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0039","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ijrobp.2010.08.052","article-title":"Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon","volume":"81","author":"Both","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.radonc.2011.07.019","article-title":"Endorectal balloon reduces anorectal doses in post-prostatectomy intensity-modulated radiotherapy","volume":"101","author":"Smeenk","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0041","article-title":"Relative biological effectiveness-clinical practice at US proton therapy centers","volume":"18","author":"L\u00fchr","year":"2025","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.adro.2026.102096_bib0042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.semradonc.2017.11.005","article-title":"Robust proton treatment planning: Physical and biological optimization","volume":"28","author":"Unkelbach","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0043","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2007.04.013","article-title":"Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study","volume":"69","author":"Lips","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0044","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1186\/s12885-023-11448-3","article-title":"Health-related quality of life of metastatic prostate cancer patients treated with prostate radiotherapy","volume":"23","author":"Ayoub","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2026.102096_bib0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2024.03.023","article-title":"Late urinary toxicity and quality of life with pelvic radiation therapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase 3 trial","volume":"120","author":"Maitre","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0046","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijrobp.2024.05.028","article-title":"Patient-reported outcomes following magnetic resonance-guided radiation therapy for prostate cancer: A systematic review and meta-analysis","volume":"120","author":"Westerhoff","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0047","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jrr\/rraf059","article-title":"Toxicity and patient-reported outcomes after moderately hypofractionated radiotherapy (60 Gy in 20 fractions) for prostate cancer: Prospective observational study","volume":"66","author":"Kikuchi","year":"2025","journal-title":"J Radiat Res"},{"key":"10.1016\/j.adro.2026.102096_bib0048","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0049","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12874-021-01419-2","article-title":"Response rate of patient reported outcomes: The delivery method matters","volume":"21","author":"Neve","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.adro.2026.102096_bib0050","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2014.55.0707","article-title":"Patient-reported outcomes and survivorship in radiation oncology: Overcoming the cons","volume":"32","author":"Siddiqui","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102096_bib0051","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: Development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.adro.2026.102096_bib0052","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.28536","article-title":"Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer","volume":"120","author":"Hoppe","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2026.102096_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2024.11.115","article-title":"Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer","volume":"122","author":"Choo","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102096_bib0054","article-title":"Pre-PROTO-PRIME: Stereotactic body proton therapy to the prostate and pelvic nodes for high risk and node-positive prostate cancer \u2014 feasibility, acute toxicity and dosimetric insights","volume":"56","author":"Chilukuri","year":"2025","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245210942600103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245210942600103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:01:41Z","timestamp":1787043701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245210942600103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S245210942600103X"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.102096","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physician- and Patient-Reported Outcomes Following Contemporary Image Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results From the Prospective PRO-Cube Study","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.102096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102096"}}